{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:52:05Z","timestamp":1781596325884,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04600-z","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:33:44Z","timestamp":1775115224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The pyrazolo[3,4-d]pyrimidine derivative CLM24 has an antineoplastic effect in aggressive dedifferentiated thyroid cancer in vitro"],"prefix":"10.1007","volume":"91","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Balestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Botrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia","family":"Rugani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Piaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concettina","family":"La Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Ulisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Virili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Varricchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Fabrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Catania","family":"Romizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giorgia","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Luconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Materazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"4600_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1053\/j.semdp.2020.03.002","volume":"37","author":"JC Hernandez-Prera","year":"2020","unstructured":"J.C. Hernandez-Prera, The evolving concept of aggressive histological variants of differentiated thyroid cancer. Semin Diagn. Pathol. 37, 228\u2013233 (2020)","journal-title":"Semin Diagn. Pathol."},{"key":"4600_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000502229","volume":"8","author":"L Fugazzola","year":"2019","unstructured":"L. Fugazzola, R. Elisei, D. Fuhrer, B. Jarzab, S. Leboulleux, K. Newbold, J. Smit, 2019 European Thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur. Thyroid J. 8, 227\u2013245 (2019)","journal-title":"Eur. Thyroid J."},{"key":"4600_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.clon.2017.02.009","volume":"29","author":"L Valerio","year":"2017","unstructured":"L. Valerio, L. Pieruzzi, C. Giani, L. Agate, V. Bottici, L. Lorusso, V. Cappagli, L. Puleo, A. Matrone, D. Viola et al., Targeted therapy in thyroid Cancer: state of the art. Clin. Oncol. (R Coll. Radiol) 29, 316\u2013324 (2017)","journal-title":"Clin. Oncol. (R Coll. Radiol)"},{"key":"4600_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1574892813666180220110729","volume":"13","author":"SM Ferrari","year":"2018","unstructured":"S.M. Ferrari, I. Ruffilli, M. Centanni, C. Virili, G. Materazzi, M. Alexopoulou, M. Miccoli, A. Antonelli, P. Fallahi, Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent. Pat. Anticancer Drug Discov. 13, 201\u2013208 (2018)","journal-title":"Recent. Pat. Anticancer Drug Discov"},{"key":"4600_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fendo.2015.00176","volume":"6","author":"SM Ferrari","year":"2015","unstructured":"S.M. Ferrari, P. Fallahi, U. Politti, G. Materazzi, E. Baldini, S. Ulisse, P. Miccoli, A. Antonelli, Molecular Targeted Therapies of Aggressive Thyroid Cancer. Front. Endocrinol. (Lausanne). 6, 176 (2015)","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4600_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/cen.15027","volume":"100","author":"J Yu","year":"2024","unstructured":"J. Yu, Z. Liu, Y. Su, X. Peng, Y. Xie, Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis. Clin. Endocrinol. (Oxf). 100, 379\u2013388 (2024)","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"4600_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11912-012-0217-0","volume":"14","author":"A Antonelli","year":"2012","unstructured":"A. Antonelli, P. Fallahi, S.M. Ferrari, C. Mancusi, M. Colaci, L. Santarpia, C. Ferri, RET TKI: potential role in thyroid cancers. Curr. Oncol. Rep. 14, 97\u2013104 (2012)","journal-title":"Curr. Oncol. Rep."},{"key":"4600_CR8","first-page":"2225","volume":"39","author":"SM Ferrari","year":"2018","unstructured":"S.M. Ferrari, G. Bocci, T. Di Desidero, G. Elia, I. Ruffilli, F. Ragusa, P. Orlandi, S.R. Paparo, A. Patrizio, S. Piaggi et al., Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol. Rep. 39, 2225\u20132234 (2018)","journal-title":"Oncol. Rep."},{"key":"4600_CR9","first-page":"2306","volume":"39","author":"SM Ferrari","year":"2018","unstructured":"S.M. Ferrari, G. Bocci, T. Di Desidero, I. Ruffilli, G. Elia, F. Ragusa, A. Fioravanti, P. Orlandi, S.R. Paparo, A. Patrizio, et al., Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. Oncol. Rep. 39, 2306\u20132314 (2018)","journal-title":"Oncol. Rep."},{"key":"4600_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3389\/fendo.2018.00764","volume":"9","author":"SM Ferrari","year":"2018","unstructured":"S.M. Ferrari, C. La Motta, G. Elia, F. Ragusa, I. Ruffilli, L. Quattrini, S.R. Paparo, S. Piaggi, A. Patrizio, S. Ulisse, et al., Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration. Front. Endocrinol. (Lausanne). 9, 764 (2018)","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"4600_CR11","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3390\/ijms24032398","volume":"24","author":"SM Ferrari","year":"2023","unstructured":"S.M. Ferrari, G. Elia, F. Ragusa, S.R. Paparo, V. Mazzi, A. Patrizio, S. Piaggi, E. Baldini, M. Centanni, C. La Motta, A. Antonelli, P. Fallahi, Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture. Int. J. Mol. Sci. 24, 2398 (2023)","journal-title":"Int. J. Mol. Sci."},{"key":"4600_CR12","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.3390\/ijms25126734","volume":"25","author":"SM Ferrari","year":"2024","unstructured":"S.M. Ferrari, F. Ragusa, G. Elia, V. Mazzi, E. Balestri, C. Botrini, L. Rugani, A. Patrizio, S. Piaggi, C. La Motta, et al., Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro. Int. J. Mol. Sci. 25, 6734 (2024)","journal-title":"Int. J. Mol. Sci."},{"key":"4600_CR13","doi-asserted-by":"publisher","first-page":"E572","DOI":"10.1210\/jc.2013-2321","volume":"99","author":"A Antonelli","year":"2014","unstructured":"A. Antonelli, G. Bocci, P. Fallahi, La C. Motta, S.M. Ferrari, C. Mancusi, A. Fioravanti, Di T. Desidero, S. Sartini, A. Corti et al., CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 99, E572\u2013E581 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4600_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12020-015-0717-4","volume":"53","author":"P Fallahi","year":"2016","unstructured":"P. Fallahi, S.M. Ferrari, C. La Motta, G. Materazzi, G. Bocci, F. Da Settimo, P. Miccoli, A. Antonelli, CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation. Endocrine. 53, 136\u2013144 (2016)","journal-title":"Endocrine"},{"key":"4600_CR15","doi-asserted-by":"publisher","first-page":"E528","DOI":"10.1210\/jc.2011-1987","volume":"97","author":"A Antonelli","year":"2012","unstructured":"A. Antonelli, G. Bocci, C. La Motta, S.M. Ferrari, P. Fallahi, I. Ruffilli, A. Di Domenicantonio, A. Fioravanti, S. Sartini, M. Minuto et al., CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 97, E528\u2013E536 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4600_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EJE-08-0190","volume":"159","author":"A Antonelli","year":"2008","unstructured":"A. Antonelli, S.M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, I. Marchetti, C. Ugolini, F. Basolo, P. Miccoli, E. Ferrannini, Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur. J. Endocrinol. 159, 283\u2013291 (2008)","journal-title":"Eur. J. Endocrinol."},{"key":"4600_CR17","first-page":"1077","volume":"62","author":"F Carlomagno","year":"2002","unstructured":"F. Carlomagno, D. Vitagliano, T. Guida, M. Napolitano, G. Vecchio, A. Fusco, A. Gazit, A. Levitzki, M. Santoro, The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 62, 1077\u20131082 (2002)","journal-title":"Cancer Res."},{"key":"4600_CR18","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1210\/jc.2002-021278","volume":"88","author":"F Carlomagno","year":"2003","unstructured":"F. Carlomagno, D. Vitagliano, T. Guida, F. Basolo, M.D. Castellone, R.M. Melillo, A. Fusco, M. Santoro, Efficient inhibition of RET\/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine (PP2). J. Clin. Endocrinol. Metab. 88, 1897\u20131902 (2003)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4600_CR19","doi-asserted-by":"publisher","first-page":"RC31","DOI":"10.1007\/BF03349220","volume":"30","author":"R Morisi","year":"2007","unstructured":"R. Morisi, M. Celano, E. Tosi, S. Schenone, M. Navarra, E. Ferretti, G. Costante, C. Durante, G. Botta, M. D\u2019Agostino et al., Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates. J. Endocrinol. Invest. 30, RC31\u2013RC34 (2007)","journal-title":"J. Endocrinol. Invest."},{"key":"4600_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1074\/jbc.271.2.695","volume":"271","author":"JH Hanke","year":"1996","unstructured":"J.H. Hanke, J.P. Gardner, R.L. Dow, P.S. Changelian, W.H. Brissette, E.J. Weringer, B.A. Pollok, P.A. Connelly, Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271, 695\u2013701 (1996)","journal-title":"J. Biol. Chem."},{"key":"4600_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrc2787","volume":"10","author":"ZA Knight","year":"2010","unstructured":"Z.A. Knight, H. Lin, K.M. Shokat, Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer. 10, 130\u2013137 (2010)","journal-title":"Nat. Rev. Cancer"},{"key":"4600_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00432-024-05714-5","volume":"150","author":"Y Kang","year":"2024","unstructured":"Y. Kang, H. Li, Y. Liu, Z. Li, Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors. J. Cancer Res. Clin. Oncol. 150, 221 (2024)","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"4600_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1054\/bjoc.2001.1797","volume":"84","author":"DR Newell","year":"2001","unstructured":"D.R. Newell, Flasks, fibres and flanks\u2013pre-clinical tumour models for predicting clinical antitumour activity. Br. J. Cancer. 84, 1289\u20131290 (2001)","journal-title":"Br. J. Cancer"},{"key":"4600_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1677\/ERC-08-0337","volume":"16","author":"A Antonelli","year":"2009","unstructured":"A. Antonelli, S.M. Ferrari, P. Fallahi, S. Frascerra, S. Piaggi, S. Gelmini, C. Lupi, M. Minuto, P. Berti, S. Benvenga et al., Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocr. Relat. Cancer. 16, 1299\u20131311 (2009)","journal-title":"Endocr. Relat. Cancer"},{"key":"4600_CR25","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1210\/jc.2011-1469","volume":"96","author":"YE Nikiforov","year":"2011","unstructured":"Y.E. Nikiforov, N.P. Ohori, S.P. Hodak, S.E. Carty, S.O. LeBeau, R.L. Ferris, L. Yip, R.R. Seethala, M.E. Tublin, M.T. Stang et al., Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J. Clin. Endocrinol. Metab. 96, 3390\u20133397 (2011)","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04600-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04600-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04600-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:58:20Z","timestamp":1781593100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04600-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4600"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04600-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article, the given and family names of Concettina La Motta were incorrectly structured. The name was displayed correctly in all versions at the time of publication. This has now been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee for Clinical trials of Pisa University Hospital (date of approval 18 November 2012).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}}],"article-number":"133"}}